3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Melanoma
23
Neoplasm Metastasis
19
Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Recurrence
10
Head and Neck Neoplasms
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Basal Cell
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Pancreatic Neoplasms
5
Glioblastoma
5
Stomach Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Fallopian Tube Neoplasms
4
Interventions
Sorafenib
61
Bevacizumab
42
Oxaliplatin
24
Doxorubicin
22
Radiosurgery
20
Gemcitabine
20
Fluorouracil
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
Capecitabine
17
lenvatinib
16
Cisplatin
16
atezolizumab
13
Leucovorin
13
Radiotherapy
11
tremelimumab
10
Cyclophosphamide
10
Carboplatin
10
Irinotecan
9
Ipilimumab
9
Drug Therapy
9
Everolimus
8
Cryosurgery
8
toripalimab
7
fludarabine
7
Sunitinib
7
Chemotherapy, Adjuvant
7
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liver Neoplasms
×
cemiplimab
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled